Company / Return on Equity (ROE)
Tempest Therapeutics, Inc. Return on Equity (ROE) History
FY2015-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-113.9%
FY2017
5-year range
-113.9% / -69.7%
FY2015-FY2017
Trend
-27.2%
vs FY2016
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Tempest Therapeutics, Inc. reports negative total equity of -113.9% in FY2017. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-113.9% in FY2017.
Declined from -69.7% to -113.9% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2017, return on equity (roe) decreased 27.2% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2017 | -113.9% | -27.2% |
| FY2016 | -89.5% | -28.5% |
| FY2015 | -69.7% | - |
As of FY2017 · SEC 10-K · Updated Jun 28, 2026